American Journal of Cancer

, Volume 5, Issue 2, pp 111–121 | Cite as

Adjuvant and Neoadjuvant Therapy for Gastric Carcinoma

An Evidence-Based Review
  • Richard N. Sullivan
  • Michael P. N. Findlay
  • John Zalcberg
Review Article


Despite its declining incidence, gastric cancer remains one of the leading causes of cancer-related death worldwide. The definitive management of localized gastric cancer has been the center of much international controversy over the years; surgery remains the mainstay, with debate centering on the required extent of lymph node resection. The role of adjuvant chemotherapy has been studied for decades, but because trials have been underpowered, it has been difficult to demonstrate a statistically significant benefit. Recently, four large meta-analyses have been published on adjuvant chemotherapy in gastric cancer. The first three have been criticized for their methodology, but the most recent meta-analysis was well conducted and showed a statistically significant benefit in favor of adjuvant chemotherapy. The heterogeneity of chemotherapy schedules included in this meta-analysis, however, makes it difficult to define the current standard. Randomized trials in the metastatic setting have shown that the combinations of epirubicin, cisplatin, and infusional fluorouracil (ECF) and docetaxel, cisplatin, and fluorouracil (TCF) have demonstrated superiority over other regimens. The role of preoperative chemotherapy is currently under investigation, with results from the MAGIC (Medical Research Council Adjuvant Gastric Infusional Chemotherapy) trial demonstrating a significant improvement in resectability, progression-free survival, and overall survival with perioperative therapy in patients with operable gastric cancer. Postoperative chemoradiotherapy has also been adopted as a standard of care in the US following the publication of the results of the Intergroup Study, INT-0116, although there remains debate over the relative benefits of more radical surgery versus the use of radiation with adjuvant treatment. It is clear that adjuvant therapy is now an appropriate addition to surgery, although there are still further questions regarding the optimal protocols.


Gastric Cancer Docetaxel Adjuvant Chemotherapy Advanced Gastric Cancer Adjuvant Systemic Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett 1998; 102–103: 227–34PubMedCrossRefGoogle Scholar
  2. 2.
    Correa P. The epidemiology of gastric cancer. World J Surg 1991; 15(2): 228–34PubMedCrossRefGoogle Scholar
  3. 3.
    Dolan K, Sutton R, Walker SJ, et al. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer 1999; 80(5–6): 834–42PubMedCrossRefGoogle Scholar
  4. 4.
    Hundahl SA, Menck HR, Mansour EG, et al. The National Cancer Data Base report on gastric carcinoma. Cancer 1997; 80(12): 2333–41PubMedCrossRefGoogle Scholar
  5. 5.
    Hansson LE, Sparen P, Nyren O. Survival in stomach cancer is improving: results of a nationwide population-based Swedish study. Ann Surg 1999; 230(2): 162–9PubMedCrossRefGoogle Scholar
  6. 6.
    Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15(1): 261–7PubMedGoogle Scholar
  7. 7.
    Roth AD, Maibach R, Fazio N, et al. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I–II trial. Ann Oncol 2004; 15(5): 759–64PubMedCrossRefGoogle Scholar
  8. 8.
    Wolfler A. Uper die Herrn Professor Billroth ausgefurten reseteionen des carcinomotousen pylorus. In: Praumuller W, editor. Vienna: 1881Google Scholar
  9. 9.
    Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I: clinical classification. Jpn J Surg 1981; 11(2): 127–39PubMedCrossRefGoogle Scholar
  10. 10.
    McCulloch P, Nita ME, Kazi H, et al. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2003; (4): CD001964Google Scholar
  11. 11.
    Soga J, Kobayashi K, Saito J, et al. The role of lymphadenectomy in curative surgery for gastric cancer. World J Surg 1979Nov; 3(6): 701–8PubMedCrossRefGoogle Scholar
  12. 12.
    Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987Aug; 11(4): 418–25PubMedCrossRefGoogle Scholar
  13. 13.
    Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79(9–10): 1522–30PubMedCrossRefGoogle Scholar
  14. 14.
    Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer: Dutch Gastric Cancer Group. N Engl J Med 1999; 340(12): 9082–142CrossRefGoogle Scholar
  15. 15.
    Wu CW. Preliminary results of gastric cancer trial in a single institute. 33rd World Congress of the International College of Surgeons; 2002 Oct 27–Nov 1; TaipeiGoogle Scholar
  16. 16.
    Deguili M, Sasako M, Garino M, et al. Outcome of D1 and D2 gastrectomy for gastric cancer: preliminary results of Italian Gastric Cancer Study Group randomized control surgical trial. 33rd World Congress of the International College of Surgeons; 2002 Oct 27–Nov 1; TaipeiGoogle Scholar
  17. 17.
    Maruyama K, Gunven P, Okabayashi K, et al. Lymph node metastases of gastric cancer: general pattern in 1931 patients. Ann Surg 1989; 210(5): 596–602PubMedCrossRefGoogle Scholar
  18. 18.
    Degiuli M, Sasako M, Ponzetto A, et al. Extended lymph node dissection for gastric cancer: results of a prospective, multi-centre analysis of morbidity and mortality in 118 consecutive cases. Eur J Surg Oncol 1997; 23(4): 310–4PubMedCrossRefGoogle Scholar
  19. 19.
    Griffith JP, Sue-Ling HM, Martin I, et al. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut 1995; 36(5): 684–90PubMedCrossRefGoogle Scholar
  20. 20.
    MacDonald JS, Woolley PV, Smythe T, et al. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979; 44(1): 42–7PubMedCrossRefGoogle Scholar
  21. 21.
    Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer: a trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9(5): 827–31PubMedGoogle Scholar
  22. 22.
    Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72(1): 37–41PubMedCrossRefGoogle Scholar
  23. 23.
    Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10(4): 541–8PubMedGoogle Scholar
  24. 24.
    Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18(14): 2648–57PubMedGoogle Scholar
  25. 25.
    Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5(7): 609–16PubMedGoogle Scholar
  26. 26.
    Einzig AI, Lipsitz S, Wiernik PH, et al. Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT): the Eastern Cooperative Oncology group (ECOG) results. Invest New Drugs 1995; 13(3): 223–7PubMedCrossRefGoogle Scholar
  27. 27.
    Ajani JA, Fairweather J, Dumas P, et al. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998; 4(4): 269–74PubMedGoogle Scholar
  28. 28.
    Futatsuki K, Wakui A, Nakao I, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer: CPT-11 Gastrointestinal Cancer Study Group. Gan to Kagaku Ryoho 1994; 21(7): 1033–8PubMedGoogle Scholar
  29. 29.
    Hennin K, Thuss-Patience P, Catane R, et al. Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer [abstract no. 993]. Proc Am Soc Clin Oncol 1999; 18: 258aGoogle Scholar
  30. 30.
    Findlay M, Ackland V, Gebski V, et al. Phase II study of irinotecan, leucovorin and 5FU (ILF) in advanced gastric cancer [abstract no. 655]. Proc Am Soc Clin Oncol 2001; 20Pt 1: 1656Google Scholar
  31. 31.
    Shirao K, Shimada Y, Kondo H, et al. Phase I–II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15(3): 921–7PubMedGoogle Scholar
  32. 32.
    Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17(1): 319–23PubMedGoogle Scholar
  33. 33.
    Ajani JA, Baker J, Pisters PW, et al. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology 2001; 15(3 Suppl. 5): 52–4PubMedGoogle Scholar
  34. 34.
    lop A, Bonura S, Manfredi A, et al. Combination of oxaliplatin, 5-fluorouracil and folinic acid in advanced/metastatic gastric carcinoma [abstract no. 60]. ASCO Gastrointestinal Cancers Symposium 2004; 2004 Jan 22–24; San Francisco (CA)Google Scholar
  35. 35.
    Cascinu S, Ficarelli R, Safi MA, et al. A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur J Cancer 1997; 33(10): 1699–702PubMedCrossRefGoogle Scholar
  36. 36.
    Bokemeyer C, Lampe CS, Clemens MR, et al. A phase II trial of paclitaxel and weekly 24h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anti Cancer Drugs 1997; 8(4): 396–9PubMedCrossRefGoogle Scholar
  37. 37.
    Kim YH, Shin SW, Kim BS, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85(2): 295–301PubMedCrossRefGoogle Scholar
  38. 38.
    Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13(2): 87–93PubMedCrossRefGoogle Scholar
  39. 39.
    Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994; 70(2): 380–3PubMedCrossRefGoogle Scholar
  40. 40.
    Mai M, Sakata Y, Kanamaru R, et al. A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). Gan to Kagaku Ryoho 1999; 26(4): 487–96PubMedGoogle Scholar
  41. 41.
    Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma: Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000; 11(3): 301–6PubMedCrossRefGoogle Scholar
  42. 42.
    Roth AD, Maibach R, Falk S, et al. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK) [abstract no. 4020]. Proc Am Soc Clin Oncol 2004; 23: 317Google Scholar
  43. 43.
    Ajani JA, van Cutzem E, Moiseyenko V, et al. Docetaxel (D), cisplatin (C), 5-fluorouracil (F) compared to cisplatin (C), 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma: interim results of a randomized phase III trial (V 325) [oral presentation]. Available from URL: [Accessed 2003]
  44. 44.
    Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract no. 710]. Proc Am Soc Clin Oncol 2001; 20Pt 1: 39Google Scholar
  45. 45.
    Anido J, Albanell J, Rojo F, et al. Inhibition by ZD1839 (iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells, [abstract no. 1712]. Proc Am Soc Clin Oncol 2001; 20Pt 1: 429aGoogle Scholar
  46. 46.
    Folli S, Dente M, Dell’Amore D, et al. Early gastric cancer: prognostic factors in 223 patients. Br J Surg 1995; 82(7): 952–6PubMedCrossRefGoogle Scholar
  47. 47.
    Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982; 8(1): 1–11PubMedCrossRefGoogle Scholar
  48. 48.
    Hallissey MT, Dunn JA, Ward LC, et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994; 343(8909): 1309–12PubMedCrossRefGoogle Scholar
  49. 49.
    Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993; 218(5): 583–92PubMedCrossRefGoogle Scholar
  50. 50.
    Allum WH, Hallissey MT, Ward LC, et al. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report: British Stomach Cancer Group. Br J Cancer 1989; 60(5): 739–44PubMedCrossRefGoogle Scholar
  51. 51.
    Budach VG. The role of radiation therapy in the management of gastric cancer. Ann Oncol 1994; 5Suppl. 3: 37–48PubMedCrossRefGoogle Scholar
  52. 52.
    Dixon WJ, Longmire JrWP, Holden WD. Use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: ten-year follow-up. Ann Surg 1971; 173(1): 26–39PubMedCrossRefGoogle Scholar
  53. 53.
    The Gastrointestinal Tumor Study Group. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982; 49(6): 1116–22CrossRefGoogle Scholar
  54. 54.
    Higgins GA, Amadeo JH, Smith DE, et al. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma: a Veterans Administration Surgical Oncology Group report. Cancer 1983; 52(6): 1105–12PubMedCrossRefGoogle Scholar
  55. 55.
    Engstrom PF, Lavin PT, Douglass JrHO, et al. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients: Eastern Cooperative Oncology Group study (EST 3275). Cancer 1985; 55(9): 1868–73PubMedCrossRefGoogle Scholar
  56. 56.
    Coombes RC, Schein PS, Chilvers CE, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer: International Collaborative Cancer Group. J Clin Oncol 1990; 8(8): 1362–9PubMedGoogle Scholar
  57. 57.
    Macdonald JS, Fleming TR, Peterson RF, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group study. Ann Surg Oncol 1995; 2(6): 488–94PubMedCrossRefGoogle Scholar
  58. 58.
    Lise M, Nitti D, Buyse M, et al. Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Recent Results Cancer Res 1988; 110: 36–43PubMedCrossRefGoogle Scholar
  59. 59.
    Neri B, deLeonardis V, Romano S, et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer 1996; 73(4): 549–52PubMedCrossRefGoogle Scholar
  60. 60.
    Neri B, Cini G, Andreoli F, et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 2001Apr 6; 84(7): 878–80PubMedCrossRefGoogle Scholar
  61. 61.
    Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003; 21(12): 2282–7PubMedCrossRefGoogle Scholar
  62. 62.
    Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11(8): 1441–7PubMedGoogle Scholar
  63. 63.
    Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35(7): 1059–64PubMedCrossRefGoogle Scholar
  64. 64.
    Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials: a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000; 11(7): 837–43PubMedCrossRefGoogle Scholar
  65. 65.
    Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous metaanalyses. Tumori 2002; 88(1): 21–7PubMedGoogle Scholar
  66. 66.
    Pignon JP, Ducreux M, Rougier P. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J Clin Oncol 1994; 12(4): 877–8PubMedGoogle Scholar
  67. 67.
    Yu W, Whang I, Suh I, et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228(3): 347–54PubMedCrossRefGoogle Scholar
  68. 68.
    Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 2001; 25(8): 985–90PubMedCrossRefGoogle Scholar
  69. 69.
    Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992; 339(8794): 629–31PubMedCrossRefGoogle Scholar
  70. 70.
    Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998; 16(8): 2733–8PubMedGoogle Scholar
  71. 71.
    Dent DM, Werner ID, Novis B, et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979; 44(2): 385–91PubMedCrossRefGoogle Scholar
  72. 72.
    Moertel CG, Childs DS, O’Fallon JR, et al. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984; 2(11): 1249–54PubMedGoogle Scholar
  73. 73.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345(10): 725–30PubMedCrossRefGoogle Scholar
  74. 74.
    Macdonald JS, Smalley SR, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction: results of Intergroup Study INT-0116 (SWOG 9008) [abstract no. 1]. American Society of Clinical Oncology Annual Meeting 2000; 2000 May 20–23; New Orleans (LA)Google Scholar
  75. 75.
    Hundahl SA, Macdonald JS, Benedetti J, et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002; 9(3): 278–86PubMedCrossRefGoogle Scholar
  76. 76.
    Bunt AM, Hermans J, Boon MC, et al. Evaluation of the extent of lymphadenectomy in a randomized trial of Western-versus Japanese-type surgery in gastric cancer. J Clin Oncol 1994; 12(2): 417–22PubMedGoogle Scholar
  77. 77.
    Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial: The Surgical Cooperative Group. Lancet 1996; 347(9007): 995–9PubMedCrossRefGoogle Scholar
  78. 78.
    Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7(9): 1318–26PubMedGoogle Scholar
  79. 79.
    Wils J, Wilke H, Lacave A, et al. Advanced gastric cancer: comparison of FAMTX (5FU, adriamycine, methotrexate) versus ELF (etroposide, 5 FU, leucovorin) versus FUP (infusional 5 FU + cisplatin): results from an EORTC trial of the GITCCG and the arbeitsgemeinschaft fur innere Onkologie (AIO). Eur J Cancer 1995; 31Suppl. 6: S116Google Scholar
  80. 80.
    Allum W, Cunningham D, Weeden S, et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971) [abstract no. 998]. Proc Am Soc Clin Oncol 2003; 22: 249Google Scholar
  81. 81.
    Hartgrink HH, van deVelde CJ, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004; 30(6): 643–9PubMedCrossRefGoogle Scholar
  82. 82.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971) [abstract no. 4001]. Proc Am Soc Clin Oncol 2005; 23(16 Pt 102): 308sGoogle Scholar
  83. 83.
    Mansfield P, Lowy A, Feig B, et al. Preoperative chemoradiation for potentially resectable gastric cancer [abstract no. 955]. Proc Am Soc Clin Oncol 2000; 19: 246aGoogle Scholar
  84. 84.
    Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22(14): 2774–80PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Richard N. Sullivan
    • 1
  • Michael P. N. Findlay
    • 2
  • John Zalcberg
    • 3
  1. 1.Regional Cancer and Blood CentreAuckland City HospitalAucklandNew Zealand
  2. 2.Cancer Trials New Zealand, School of Medical SciencesThe University of AucklandAucklandNew Zealand
  3. 3.Division of Haematology and Medical OncologyPeter MacCallum Cancer CentreMelbourneAustralia

Personalised recommendations